REG - SkinBioTherapeutics - Update On Board Investigation and Interims Date

SkinbiotherapeuticsAnnouncement

Today 11:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260320:nRST5100Xa&default-theme=true

RNS Number : 5100X  SkinBioTherapeutics PLC  20 March 2026

 

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company" or the "Group")

 

Update On Board Investigation, Interim Results

and Expected Suspension of Trading

 

·      HY26 results to be delayed until Board Investigation is complete

·      Shares expected to be suspended from 1 April 2026 until HY26
results are published

 

20 March 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life
science business focused on skin health, updates shareholders on the timing
for the interim results for the 6 months ended 31 December 2025 ("Interim
Results") and the ongoing Board investigation.

 

As announced on 20 February 2026, the Board appointed FRP Advisory to
undertake an independent, forensic review into the matters outlined by the
Company on Monday 16 February 2026
(https://irs.nbtrader.co.uk/ir/SkinBiotix/newsArticle.php?id=311428261629691589&ST=SBTX)
. Whilst progress is being made, this forensic review is ongoing and
accordingly, the Company will not be in a position to announce the Interim
Results by 31 March 2026, as required by the AIM Rules for Companies.

 

Consequently, the Board expects that trading in the Company's ordinary shares
will be suspended with effect from 7.30am on 1 April 2026. Trading in the
shares is anticipated to resume upon the finalisation of the Board
investigation and the publication of the Interim Results.

 

The Company has a robust cash position of £2.44m as at the close of 19 March
2026 and its businesses are trading on a "business as usual" basis.

 

The Board will update shareholders on the result of the forensic review and
Board investigation as soon as possible.

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic
law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

 

-Ends-

For more information please contact:

 SkinBioTherapeutics plc                                  ir@skinbiotix.com
 Martin Hunt, Executive Chairman

Rachel Parsonage, Interim CEO

Emily Bertram, CFO
 Singer Capital Markets (Nominated Adviser & Broker)      +44 (0) 020 7496 3000

Philip Davies

James Todd

Patrick Weaver
 Vigo Consulting                                          +44 (0) 20 7390 0230
 Melanie Toyne-Sewell, Rozi Morris                        SkinBio@vigoconsulting.com

 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Group's proprietary platform technology, SkinBiotix(®), is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Group's foundation business is targeting the skin healthcare market via
five pillars, the most advanced of which are cosmetic skincare
(SkinBiotix(®)) and food supplements that harness the gut-skin axis
(AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where
SkinBiotix(®) is being used as an active skin ingredient with the Croda trade
name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting
the symptoms of inflammatory skin conditions, being sold directly and via
Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in
complementary areas such as skincare and cosmetic applications, that also
bring new distribution and geographical platforms, and manufacturing
capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.SkinBioTherapeutics.com
(http://www.skinbiotherapeutics.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBBGDXGDDDGLG



            Copyright 2019 Regulatory News Service, all rights reserved